Drug evaluation: lexatumumab, an intravenous human agonistic mAb targeting TRAIL receptor 2.
Human Genome Sciences Inc, under license from Cambridge Antibody Technology Ltd, is developing lexatumumab, an intravenous human agonistic mAb to TNF-related apoptosis-inducing ligand (TRAIL) receptor 2, for the potential treatment of cancer. Phase II clinical trials of lexatumumab are underway.
Marini
Patrizia
P
University of Tübingen, Department of Radiation Oncology, Hoppe-Seyler-Str 3, D-72076, Tübingen, Germany. patrizia.marini@uni-tuebingen.de
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D017209:Apoptosis; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D004353:Drug Evaluation, Preclinical; D006801:Humans; D066298:In Vitro Techniques; D007275:Injections, Intravenous; D009369:Neoplasms / Q000473:pathology / Q000628:therapy; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand / Q000819:agonists*; D013329:Structure-Activity Relationship
D000911:Antibodies, Monoclonal; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand; C510234:lexatumumab